Reversal of target-specific oral anticoagulants

Drug Discovery Today

Volumn 19, Issue 9, 2014, Pages 1465-1470

  Siegal, Deborah M ^a   Cuker, Adam ^b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANDEXANET ALFA; ANTICOAGULANT AGENT; APIXABAN; BETRIXABAN; DABIGATRAN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; ANTIDOTE; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HUMAN; IN VITRO STUDY; MORTALITY; NONHUMAN; REVIEW; SINGLE DRUG DOSE; ANIMAL; CHEMICALLY INDUCED; COMPARATIVE STUDY; DISEASE MODEL; HEMORRHAGE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; ANTIDOTES; ANTITHROMBINS; DISEASE MODELS, ANIMAL; FACTOR XA INHIBITORS; HEMORRHAGE; HUMANS;

EID: 84907813416     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.05.013     Document Type: Review

References (42)

1. F. Dentali Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature Circulation 126 2012 2381 2391
2. B.D. Fox Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials BMJ 345 2012 e7498
3. I. Neumann Oral direct factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis Ann. Intern. Med. 156 2012 710 719
4. S. Pandey, and G.N. Vyas Adverse effects of plasma transfusion Transfusion 52 Suppl. 1 2012 65 79
5. F. Dentali Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis Thromb. Haemost. 106 2011 429 438
6. N.S. Key, and C. Negrier Coagulation factor concentrates: past, present, and future Lancet 370 2007 439 448
7. H.J. Ehrlich Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events Haemophilia 8 2002 83 90
8. L.M. Aledort Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity J. Thromb. Haemost. 2 2004 1700 1708
9. M. Levi Safety of recombinant activated factor VII in randomized clinical trials N. Engl. J. Med. 363 2010 1791 1800
10. F. Schiele A specific antidote for dabigatran: functional and structural characterization Blood 121 2013 3554 3562
11. G. Lu A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa Nat. Med. 19 2013 446 451
12. N. Thalji Reversal for factor Xa inhibitors using factor Xa zymogen-like variants J. Thromb. Haemost. 11 2013 167
13. B. Laulicht Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977 J. Thromb. Haemost. 11 2013 75
14. D. Garcia Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants J. Thromb. Haemost. 11 2013 245 252
15. E.S. Eerenberg Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects Circulation 124 2011 1573 1579
16. R. Marlu Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers Thromb. Haemost. 108 2012 217 224
17. T.L. Khoo The use of FEIBA(R) in the correction of coagulation abnormalities induced by dabigatran Int. J. Lab. Hematol. 35 2013 222 224
18. R. Herrmann Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban Thromb. Haemost. 111 2014 989 995
19. J. Stangier, and M. Feuring Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran Blood Coagul. Fibrinolysis 23 2012 138 143
20. M.D. Lambourne Prothrombin complex concentrates reduce blood loss in mice rendered coagulopathic by warfarin but not dabigatran etexilate Transfusion 52 2012 56A 57A
21. W. Zhou Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran Stroke 42 2011 3594 3599
22. I. Pragst Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model J. Thromb. Haemost. 10 2012 1841 1848
23. J. van Ryn In vitro characterization, pharmacokinetics and reversal of supratherapeutic doses of dabigtran-induced bleeding in rats by a specific antibody fragment antidote to dabigtran Blood 120 2012 meeting abstract 3418
24. J. Toth Reversal of dabigtran's anticoagulant activity in the monkey by a specific antidote and pharmacokinetic and pharmacodynamic modeling Blood 120 2012 meeting abstract 22
25. J. Dinkelaar In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for rivaroxaban J. Thromb. Haemost. 11 2013 1111 1118
26. M.K. Korber Measurement and reversal of prophylactic and therapeutic peak levels of rivaroxaban: an in vitro study Clin. Appl. Thromb. Hemost. 2013 10.1177/1076029613494468
27. G. Escolar Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood PLoS One 8 2013 e78696
28. T. Fukuda Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents Thromb. Haemost. 107 2012 253 259
29. A. Godier Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model Anesthesiology 116 2012 94 102
30. E. Perzborn Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates Thromb. Haemost. 110 2013 162 172
31. M. Crowther A phase 2 randomized, double-blind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors J. Thromb. Haemost. 11 2013 30
32. D.M. Siegal, and A. Cuker Reversal of novel oral anticoagulants in patients with major bleeding J. Thromb. Thrombolysis 35 2013 391 398
33. J. Stangier The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects Br. J. Clin. Pharmacol. 64 2007 292 303
34. S. Blech The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans Drug Metab. Dispos. 36 2008 386 399
35. D. Kubitza Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor Clin. Pharmacol. Ther. 78 2005 412 421
36. D. Kubitza Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct factor Xa inhibitor - after multiple dosing in healthy male subjects Eur. J. Clin. Pharmacol. 61 2005 873 880
37. C. Weinz Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans Drug Metab. Dispos. 37 2009 1056 1064
38. N. Raghavan Apixaban metabolism and pharmacokinetics after oral administration to humans Drug Metab. Dispos. 37 2009 74 81
39. C. Frost Apixaban, an oral, direct factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects Br. J. Clin. Pharmacol. 75 2013 476 487
40. Y.C. Barrett A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects Thromb. Haemost. 107 2012 916 924
41. B.I. Eriksson Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development Clin. Pharmacokinet. 48 2009 1 22
42. M. Palladino Evaluation of the oral direct factor Xa inhibitor - betrixaban Expert Opin. Investig. Drugs 22 2013 1465 1472